CVS Health Replaces Humira with Hyrimoz on April 1, Biosimilar Market Share Surges to 36%

Apr 16, 2024, 02:25 PM

Following a strategic decision by CVS Health, credited by analysts including Elizabeth Anderson from Evercore ISI, there has been a significant increase in the prescription rates of biosimilar versions of Humira, specifically Hyrimoz. CVS Health removed Humira from its major commercial formularies on April 1st and replaced it with Hyrimoz, a biosimilar jointly marketed by its subsidiary Cordavis. This change led to a surge in new prescriptions for Hyrimoz, with the market share of biosimilar versions of Humira jumping from 5% to 36% in just the first week of April.